Skip to main content
. 2021 Mar 19;7(1):33–42. doi: 10.3233/BLC-200377

Fig. 2.

Fig. 2

Overall Survival Comparisons by Initial Treatment. A. Early Bone Metastases (eBM); For patients with eBM treated with immune checkpoint inhibitors versus platinum, overall survival was 1.6 vs 9.1 months (p = 0.02). B. No Early Bone Metastases (nBM). For patients with nBM treated with immune checkpoint inhibitors versus platinum, overall survival was 11.8 vs 15.8 months (p = 0.11).